Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

News Conference News TCT 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

L.A. McKeown

September 28, 2019

News Industry News

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

September 27, 2019

News Daily News

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

Todd Neale

August 07, 2019

News Industry News

Boston Scientific Responds to the FDA’s Guidance on Use of Peripheral Paclitaxel Devices for Treatment of PAD

August 07, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for June 2019

Shelley Wood

June 28, 2019

News Daily News

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

L.A. McKeown

June 19, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2019

Caitlin E. Cox

May 31, 2019

News Conference News EuroPCR 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

L.A. McKeown

May 23, 2019

News Conference News ACC 2019

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

Michael O'Riordan

March 18, 2019

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

L.A. McKeown

March 06, 2019

News Daily News

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

L.A. McKeown

March 01, 2019

News Daily News

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

L.A. McKeown

March 01, 2019

News Daily News

Mortality Data ‘Inadvertently Omitted’ From IN.PACT Analysis of Paclitaxel-Coated Balloons

L.A. McKeown

February 19, 2019

News Daily News

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

L.A. McKeown

February 13, 2019

Presentation ISET 2019

Drug-Coated Therapy for ISR: Review of Options and Data

Presenter: Brian DeRubertis

January 30, 2019

Presentation ISET 2019

5-Year Results from the IN.PACT SFA Randomized Trial

Presenter: Gary Ansel

January 30, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Daily News

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

L.A. McKeown

February 11, 2018

Advertisement

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

FDA Gives Eagerly Awaited Update on Mortality With Paclitaxel-Coated Devices in PAD

Boston Scientific Responds to the FDA’s Guidance on Use of Peripheral Paclitaxel Devices for Treatment of PAD

TCTMD’s Top 10 Most Popular Stories for June 2019

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

TCTMD’s Top 10 Most Popular Stories for May 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

No Excess Mortality Risk With Paclitaxel Stents in PAD, Second Medicare Analysis Finds

Mortality Data ‘Inadvertently Omitted’ From IN.PACT Analysis of Paclitaxel-Coated Balloons

Medicare Analysis Offers More Reassurances in Hullabaloo Over Paclitaxel-Based PAD Devices

Drug-Coated Therapy for ISR: Review of Options and Data

5-Year Results from the IN.PACT SFA Randomized Trial

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

REAL PTX: Head-to-Head DCB, DES Data in PAD Show Trend Favoring Stenting at 36 Months

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content